Roger Crystal Sells 1,058 Shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Roger Crystal sold 1,058 shares of the business’s stock in a transaction dated Monday, January 10th. The stock was sold at an average price of $30.49, for a total transaction of $32,258.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of OPNT opened at $27.07 on Friday. The company’s 50 day moving average price is $30.12 and its 200 day moving average price is $23.26. Opiant Pharmaceuticals, Inc. has a 52 week low of $8.51 and a 52 week high of $37.71. The company has a market capitalization of $127.77 million, a PE ratio of 541.51 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.23 and a current ratio of 9.23.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its earnings results on Thursday, November 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.41. The firm had revenue of $16.34 million during the quarter, compared to analysts’ expectations of $12.45 million. Opiant Pharmaceuticals had a net margin of 3.58% and a return on equity of 4.25%. During the same period in the previous year, the company earned $0.15 earnings per share. On average, equities analysts forecast that Opiant Pharmaceuticals, Inc. will post 0.39 earnings per share for the current fiscal year.

Separately, Oppenheimer assumed coverage on shares of Opiant Pharmaceuticals in a research note on Wednesday, December 8th. They issued an “outperform” rating and a $42.00 price objective on the stock.

Several institutional investors have recently modified their holdings of the company. Morgan Stanley raised its stake in Opiant Pharmaceuticals by 11.8% during the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock valued at $101,000 after purchasing an additional 1,000 shares during the last quarter. Advisor Group Holdings Inc. raised its stake in Opiant Pharmaceuticals by 102.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock valued at $163,000 after purchasing an additional 3,200 shares during the last quarter. Northern Trust Corp raised its stake in Opiant Pharmaceuticals by 17.6% during the 2nd quarter. Northern Trust Corp now owns 37,958 shares of the technology company’s stock valued at $507,000 after purchasing an additional 5,668 shares during the last quarter. BlackRock Inc. raised its stake in Opiant Pharmaceuticals by 107.2% during the 3rd quarter. BlackRock Inc. now owns 24,686 shares of the technology company’s stock valued at $635,000 after purchasing an additional 12,774 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in Opiant Pharmaceuticals during the 3rd quarter valued at $638,000. Institutional investors and hedge funds own 26.90% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

See Also: Google Finance Portfolio Tips and Tricks

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.